nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR7—vas deferens—prostate cancer	0.0396	0.522	CbGeAlD
Methysergide—HTR2A—urine—prostate cancer	0.00615	0.0809	CbGeAlD
Methysergide—SIGMAR1—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.00612	1	CbGdCrCtD
Methysergide—SIGMAR1—prostate gland—prostate cancer	0.00414	0.0545	CbGeAlD
Methysergide—SIGMAR1—seminal vesicle—prostate cancer	0.0035	0.0461	CbGeAlD
Methysergide—SIGMAR1—urethra—prostate cancer	0.00277	0.0365	CbGeAlD
Methysergide—HTR7—epithelium—prostate cancer	0.0026	0.0342	CbGeAlD
Methysergide—HTR1A—renal system—prostate cancer	0.00252	0.0332	CbGeAlD
Methysergide—HTR7—renal system—prostate cancer	0.00241	0.0317	CbGeAlD
Methysergide—SIGMAR1—bone marrow—prostate cancer	0.00213	0.0281	CbGeAlD
Methysergide—SIGMAR1—testis—prostate cancer	0.00182	0.024	CbGeAlD
Methysergide—HTR2A—epithelium—prostate cancer	0.00162	0.0213	CbGeAlD
Methysergide—HTR7—testis—prostate cancer	0.00156	0.0205	CbGeAlD
Methysergide—HTR2A—renal system—prostate cancer	0.0015	0.0198	CbGeAlD
Methysergide—SIGMAR1—lymph node—prostate cancer	0.00132	0.0174	CbGeAlD
Methysergide—HTR2B—lymph node—prostate cancer	0.00132	0.0174	CbGeAlD
Methysergide—Ergonovine—CYP3A4—prostate cancer	0.00109	0.28	CrCbGaD
Methysergide—HTR2A—testis—prostate cancer	0.000972	0.0128	CbGeAlD
Methysergide—Methylergometrine—CYP3A4—prostate cancer	0.000952	0.245	CrCbGaD
Methysergide—Lisuride—CYP3A4—prostate cancer	0.000639	0.164	CrCbGaD
Methysergide—Weight decreased—Prednisone—prostate cancer	0.000618	0.000963	CcSEcCtD
Methysergide—Ill-defined disorder—Etoposide—prostate cancer	0.000616	0.00096	CcSEcCtD
Methysergide—Dyspepsia—Estradiol—prostate cancer	0.000615	0.000959	CcSEcCtD
Methysergide—Ergotamine—CYP3A4—prostate cancer	0.000614	0.158	CrCbGaD
Methysergide—Oedema peripheral—Capecitabine—prostate cancer	0.000604	0.000942	CcSEcCtD
Methysergide—Gastrointestinal disorder—Estradiol—prostate cancer	0.000603	0.000941	CcSEcCtD
Methysergide—Diarrhoea—Goserelin—prostate cancer	0.000603	0.000941	CcSEcCtD
Methysergide—Fatigue—Estradiol—prostate cancer	0.000602	0.00094	CcSEcCtD
Methysergide—Malaise—Etoposide—prostate cancer	0.000598	0.000933	CcSEcCtD
Methysergide—Pain—Estradiol—prostate cancer	0.000598	0.000932	CcSEcCtD
Methysergide—Constipation—Estradiol—prostate cancer	0.000598	0.000932	CcSEcCtD
Methysergide—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000597	0.000932	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000593	0.000925	CcSEcCtD
Methysergide—Bromocriptine—CYP3A4—prostate cancer	0.000592	0.152	CrCbGaD
Methysergide—Flushing—Docetaxel—prostate cancer	0.000588	0.000917	CcSEcCtD
Methysergide—Paraesthesia—Mitoxantrone—prostate cancer	0.000585	0.000912	CcSEcCtD
Methysergide—Dizziness—Goserelin—prostate cancer	0.000583	0.000909	CcSEcCtD
Methysergide—Ataxia—Epirubicin—prostate cancer	0.000581	0.000906	CcSEcCtD
Methysergide—Dyspnoea—Mitoxantrone—prostate cancer	0.000581	0.000905	CcSEcCtD
Methysergide—Somnolence—Mitoxantrone—prostate cancer	0.000579	0.000903	CcSEcCtD
Methysergide—Dizziness—Conjugated Estrogens—prostate cancer	0.000577	0.000901	CcSEcCtD
Methysergide—Feeling abnormal—Estradiol—prostate cancer	0.000576	0.000898	CcSEcCtD
Methysergide—Convulsion—Etoposide—prostate cancer	0.000575	0.000897	CcSEcCtD
Methysergide—Dyspepsia—Mitoxantrone—prostate cancer	0.000573	0.000894	CcSEcCtD
Methysergide—Pain in extremity—Doxorubicin—prostate cancer	0.000572	0.000891	CcSEcCtD
Methysergide—Gastrointestinal pain—Estradiol—prostate cancer	0.000571	0.000891	CcSEcCtD
Methysergide—Flushing—Capecitabine—prostate cancer	0.000569	0.000888	CcSEcCtD
Methysergide—Chest pain—Etoposide—prostate cancer	0.000565	0.000881	CcSEcCtD
Methysergide—Orthostatic hypotension—Epirubicin—prostate cancer	0.000564	0.00088	CcSEcCtD
Methysergide—Fatigue—Mitoxantrone—prostate cancer	0.000561	0.000876	CcSEcCtD
Methysergide—Vomiting—Goserelin—prostate cancer	0.00056	0.000874	CcSEcCtD
Methysergide—Alopecia—Docetaxel—prostate cancer	0.00056	0.000873	CcSEcCtD
Methysergide—Discomfort—Etoposide—prostate cancer	0.000558	0.000871	CcSEcCtD
Methysergide—Pain—Mitoxantrone—prostate cancer	0.000557	0.000868	CcSEcCtD
Methysergide—Constipation—Mitoxantrone—prostate cancer	0.000557	0.000868	CcSEcCtD
Methysergide—Rash—Goserelin—prostate cancer	0.000556	0.000867	CcSEcCtD
Methysergide—Dermatitis—Goserelin—prostate cancer	0.000555	0.000866	CcSEcCtD
Methysergide—Vomiting—Conjugated Estrogens—prostate cancer	0.000555	0.000866	CcSEcCtD
Methysergide—Abdominal pain—Estradiol—prostate cancer	0.000552	0.000862	CcSEcCtD
Methysergide—Body temperature increased—Estradiol—prostate cancer	0.000552	0.000862	CcSEcCtD
Methysergide—Rash—Conjugated Estrogens—prostate cancer	0.000551	0.000859	CcSEcCtD
Methysergide—Dermatitis—Conjugated Estrogens—prostate cancer	0.00055	0.000858	CcSEcCtD
Methysergide—Alopecia—Capecitabine—prostate cancer	0.000542	0.000845	CcSEcCtD
Methysergide—Ataxia—Doxorubicin—prostate cancer	0.000537	0.000838	CcSEcCtD
Methysergide—Feeling abnormal—Mitoxantrone—prostate cancer	0.000537	0.000837	CcSEcCtD
Methysergide—Back pain—Docetaxel—prostate cancer	0.000533	0.000832	CcSEcCtD
Methysergide—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000532	0.00083	CcSEcCtD
Methysergide—Thrombocytopenia—Etoposide—prostate cancer	0.00053	0.000827	CcSEcCtD
Methysergide—Tachycardia—Etoposide—prostate cancer	0.000529	0.000824	CcSEcCtD
Methysergide—Eosinophilia—Epirubicin—prostate cancer	0.000529	0.000824	CcSEcCtD
Methysergide—Nausea—Goserelin—prostate cancer	0.000524	0.000817	CcSEcCtD
Methysergide—Orthostatic hypotension—Doxorubicin—prostate cancer	0.000522	0.000814	CcSEcCtD
Methysergide—Nausea—Conjugated Estrogens—prostate cancer	0.000519	0.000809	CcSEcCtD
Methysergide—Back pain—Capecitabine—prostate cancer	0.000517	0.000806	CcSEcCtD
Methysergide—Abdominal pain—Mitoxantrone—prostate cancer	0.000515	0.000803	CcSEcCtD
Methysergide—Body temperature increased—Mitoxantrone—prostate cancer	0.000515	0.000803	CcSEcCtD
Methysergide—Flushing—Prednisone—prostate cancer	0.000507	0.000791	CcSEcCtD
Methysergide—Asthenia—Estradiol—prostate cancer	0.000501	0.000782	CcSEcCtD
Methysergide—Dysuria—Epirubicin—prostate cancer	0.000499	0.000779	CcSEcCtD
Methysergide—Neutropenia—Epirubicin—prostate cancer	0.000499	0.000779	CcSEcCtD
Methysergide—Ill-defined disorder—Capecitabine—prostate cancer	0.000495	0.000773	CcSEcCtD
Methysergide—Eosinophilia—Doxorubicin—prostate cancer	0.000489	0.000763	CcSEcCtD
Methysergide—Paraesthesia—Etoposide—prostate cancer	0.000486	0.000759	CcSEcCtD
Methysergide—Weight increased—Epirubicin—prostate cancer	0.000486	0.000758	CcSEcCtD
Methysergide—Weight decreased—Epirubicin—prostate cancer	0.000483	0.000753	CcSEcCtD
Methysergide—Dyspnoea—Etoposide—prostate cancer	0.000483	0.000753	CcSEcCtD
Methysergide—Alopecia—Prednisone—prostate cancer	0.000483	0.000753	CcSEcCtD
Methysergide—Malaise—Capecitabine—prostate cancer	0.000482	0.000751	CcSEcCtD
Methysergide—Somnolence—Etoposide—prostate cancer	0.000481	0.000751	CcSEcCtD
Methysergide—Diarrhoea—Estradiol—prostate cancer	0.000478	0.000746	CcSEcCtD
Methysergide—Convulsion—Docetaxel—prostate cancer	0.000478	0.000745	CcSEcCtD
Methysergide—Drowsiness—Epirubicin—prostate cancer	0.000476	0.000742	CcSEcCtD
Methysergide—Chest pain—Docetaxel—prostate cancer	0.00047	0.000732	CcSEcCtD
Methysergide—Myalgia—Docetaxel—prostate cancer	0.00047	0.000732	CcSEcCtD
Methysergide—Arthralgia—Docetaxel—prostate cancer	0.00047	0.000732	CcSEcCtD
Methysergide—Gastrointestinal disorder—Etoposide—prostate cancer	0.000468	0.000729	CcSEcCtD
Methysergide—Asthenia—Mitoxantrone—prostate cancer	0.000467	0.000729	CcSEcCtD
Methysergide—Fatigue—Etoposide—prostate cancer	0.000467	0.000728	CcSEcCtD
Methysergide—Constipation—Etoposide—prostate cancer	0.000463	0.000722	CcSEcCtD
Methysergide—Pain—Etoposide—prostate cancer	0.000463	0.000722	CcSEcCtD
Methysergide—Dizziness—Estradiol—prostate cancer	0.000462	0.000721	CcSEcCtD
Methysergide—Dysuria—Doxorubicin—prostate cancer	0.000462	0.00072	CcSEcCtD
Methysergide—Neutropenia—Doxorubicin—prostate cancer	0.000462	0.00072	CcSEcCtD
Methysergide—Arthralgia—Capecitabine—prostate cancer	0.000455	0.000709	CcSEcCtD
Methysergide—Chest pain—Capecitabine—prostate cancer	0.000455	0.000709	CcSEcCtD
Methysergide—Myalgia—Capecitabine—prostate cancer	0.000455	0.000709	CcSEcCtD
Methysergide—Oedema—Docetaxel—prostate cancer	0.00045	0.000702	CcSEcCtD
Methysergide—Weight increased—Doxorubicin—prostate cancer	0.00045	0.000701	CcSEcCtD
Methysergide—Discomfort—Capecitabine—prostate cancer	0.000449	0.000701	CcSEcCtD
Methysergide—Weight decreased—Doxorubicin—prostate cancer	0.000447	0.000697	CcSEcCtD
Methysergide—Feeling abnormal—Etoposide—prostate cancer	0.000446	0.000696	CcSEcCtD
Methysergide—Diarrhoea—Mitoxantrone—prostate cancer	0.000446	0.000695	CcSEcCtD
Methysergide—Vomiting—Estradiol—prostate cancer	0.000444	0.000693	CcSEcCtD
Methysergide—Gastrointestinal pain—Etoposide—prostate cancer	0.000443	0.000691	CcSEcCtD
Methysergide—Ill-defined disorder—Prednisone—prostate cancer	0.000441	0.000688	CcSEcCtD
Methysergide—Thrombocytopenia—Docetaxel—prostate cancer	0.000441	0.000687	CcSEcCtD
Methysergide—Rash—Estradiol—prostate cancer	0.000441	0.000687	CcSEcCtD
Methysergide—Drowsiness—Doxorubicin—prostate cancer	0.00044	0.000687	CcSEcCtD
Methysergide—Dermatitis—Estradiol—prostate cancer	0.00044	0.000687	CcSEcCtD
Methysergide—Tachycardia—Docetaxel—prostate cancer	0.000439	0.000685	CcSEcCtD
Methysergide—Oedema—Capecitabine—prostate cancer	0.000436	0.00068	CcSEcCtD
Methysergide—Malaise—Prednisone—prostate cancer	0.000429	0.000669	CcSEcCtD
Methysergide—Abdominal pain—Etoposide—prostate cancer	0.000428	0.000668	CcSEcCtD
Methysergide—Body temperature increased—Etoposide—prostate cancer	0.000428	0.000668	CcSEcCtD
Methysergide—Thrombocytopenia—Capecitabine—prostate cancer	0.000427	0.000665	CcSEcCtD
Methysergide—Tachycardia—Capecitabine—prostate cancer	0.000425	0.000663	CcSEcCtD
Methysergide—Oedema peripheral—Epirubicin—prostate cancer	0.000421	0.000657	CcSEcCtD
Methysergide—Nausea—Estradiol—prostate cancer	0.000415	0.000647	CcSEcCtD
Methysergide—Vomiting—Mitoxantrone—prostate cancer	0.000414	0.000646	CcSEcCtD
Methysergide—Convulsion—Prednisone—prostate cancer	0.000412	0.000643	CcSEcCtD
Methysergide—Rash—Mitoxantrone—prostate cancer	0.000411	0.00064	CcSEcCtD
Methysergide—Dermatitis—Mitoxantrone—prostate cancer	0.00041	0.00064	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.00041	0.00064	CcSEcCtD
Methysergide—Insomnia—Docetaxel—prostate cancer	0.000407	0.000635	CcSEcCtD
Methysergide—Myalgia—Prednisone—prostate cancer	0.000405	0.000632	CcSEcCtD
Methysergide—Arthralgia—Prednisone—prostate cancer	0.000405	0.000632	CcSEcCtD
Methysergide—Paraesthesia—Docetaxel—prostate cancer	0.000404	0.00063	CcSEcCtD
Methysergide—Dyspnoea—Docetaxel—prostate cancer	0.000401	0.000626	CcSEcCtD
Methysergide—Somnolence—Docetaxel—prostate cancer	0.0004	0.000624	CcSEcCtD
Methysergide—Discomfort—Prednisone—prostate cancer	0.0004	0.000624	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000397	0.000619	CcSEcCtD
Methysergide—Flushing—Epirubicin—prostate cancer	0.000397	0.000619	CcSEcCtD
Methysergide—Dyspepsia—Docetaxel—prostate cancer	0.000396	0.000618	CcSEcCtD
Methysergide—Insomnia—Capecitabine—prostate cancer	0.000394	0.000615	CcSEcCtD
Methysergide—Paraesthesia—Capecitabine—prostate cancer	0.000391	0.00061	CcSEcCtD
Methysergide—Oedema peripheral—Doxorubicin—prostate cancer	0.00039	0.000607	CcSEcCtD
Methysergide—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000389	0.000606	CcSEcCtD
Methysergide—Asthenia—Etoposide—prostate cancer	0.000389	0.000606	CcSEcCtD
Methysergide—Dyspnoea—Capecitabine—prostate cancer	0.000389	0.000606	CcSEcCtD
Methysergide—Oedema—Prednisone—prostate cancer	0.000388	0.000605	CcSEcCtD
Methysergide—Fatigue—Docetaxel—prostate cancer	0.000388	0.000605	CcSEcCtD
Methysergide—Nausea—Mitoxantrone—prostate cancer	0.000387	0.000603	CcSEcCtD
Methysergide—Pain—Docetaxel—prostate cancer	0.000385	0.0006	CcSEcCtD
Methysergide—Constipation—Docetaxel—prostate cancer	0.000385	0.0006	CcSEcCtD
Methysergide—Dyspepsia—Capecitabine—prostate cancer	0.000384	0.000598	CcSEcCtD
Methysergide—Tachycardia—Prednisone—prostate cancer	0.000379	0.000591	CcSEcCtD
Methysergide—Alopecia—Epirubicin—prostate cancer	0.000378	0.000589	CcSEcCtD
Methysergide—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000376	0.000587	CcSEcCtD
Methysergide—Fatigue—Capecitabine—prostate cancer	0.000376	0.000586	CcSEcCtD
Methysergide—Pain—Capecitabine—prostate cancer	0.000373	0.000581	CcSEcCtD
Methysergide—Constipation—Capecitabine—prostate cancer	0.000373	0.000581	CcSEcCtD
Methysergide—Feeling abnormal—Docetaxel—prostate cancer	0.000371	0.000578	CcSEcCtD
Methysergide—Diarrhoea—Etoposide—prostate cancer	0.000371	0.000578	CcSEcCtD
Methysergide—Gastrointestinal pain—Docetaxel—prostate cancer	0.000368	0.000574	CcSEcCtD
Methysergide—Flushing—Doxorubicin—prostate cancer	0.000367	0.000572	CcSEcCtD
Methysergide—Back pain—Epirubicin—prostate cancer	0.00036	0.000561	CcSEcCtD
Methysergide—Feeling abnormal—Capecitabine—prostate cancer	0.000359	0.00056	CcSEcCtD
Methysergide—Dizziness—Etoposide—prostate cancer	0.000358	0.000559	CcSEcCtD
Methysergide—Gastrointestinal pain—Capecitabine—prostate cancer	0.000356	0.000556	CcSEcCtD
Methysergide—Abdominal pain—Docetaxel—prostate cancer	0.000356	0.000555	CcSEcCtD
Methysergide—Body temperature increased—Docetaxel—prostate cancer	0.000356	0.000555	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000354	0.000552	CcSEcCtD
Methysergide—Insomnia—Prednisone—prostate cancer	0.000351	0.000548	CcSEcCtD
Methysergide—Alopecia—Doxorubicin—prostate cancer	0.000349	0.000545	CcSEcCtD
Methysergide—Paraesthesia—Prednisone—prostate cancer	0.000349	0.000544	CcSEcCtD
Methysergide—Ill-defined disorder—Epirubicin—prostate cancer	0.000345	0.000538	CcSEcCtD
Methysergide—Abdominal pain—Capecitabine—prostate cancer	0.000344	0.000537	CcSEcCtD
Methysergide—Body temperature increased—Capecitabine—prostate cancer	0.000344	0.000537	CcSEcCtD
Methysergide—Vomiting—Etoposide—prostate cancer	0.000344	0.000537	CcSEcCtD
Methysergide—Dyspepsia—Prednisone—prostate cancer	0.000342	0.000533	CcSEcCtD
Methysergide—Rash—Etoposide—prostate cancer	0.000341	0.000533	CcSEcCtD
Methysergide—Dermatitis—Etoposide—prostate cancer	0.000341	0.000532	CcSEcCtD
Methysergide—Malaise—Epirubicin—prostate cancer	0.000335	0.000523	CcSEcCtD
Methysergide—Fatigue—Prednisone—prostate cancer	0.000335	0.000522	CcSEcCtD
Methysergide—Back pain—Doxorubicin—prostate cancer	0.000333	0.000519	CcSEcCtD
Methysergide—Constipation—Prednisone—prostate cancer	0.000332	0.000518	CcSEcCtD
Methysergide—Asthenia—Docetaxel—prostate cancer	0.000323	0.000504	CcSEcCtD
Methysergide—Convulsion—Epirubicin—prostate cancer	0.000322	0.000503	CcSEcCtD
Methysergide—Nausea—Etoposide—prostate cancer	0.000322	0.000502	CcSEcCtD
Methysergide—Feeling abnormal—Prednisone—prostate cancer	0.00032	0.000499	CcSEcCtD
Methysergide—Ill-defined disorder—Doxorubicin—prostate cancer	0.000319	0.000498	CcSEcCtD
Methysergide—Gastrointestinal pain—Prednisone—prostate cancer	0.000317	0.000495	CcSEcCtD
Methysergide—Arthralgia—Epirubicin—prostate cancer	0.000317	0.000494	CcSEcCtD
Methysergide—Chest pain—Epirubicin—prostate cancer	0.000317	0.000494	CcSEcCtD
Methysergide—Myalgia—Epirubicin—prostate cancer	0.000317	0.000494	CcSEcCtD
Methysergide—Discomfort—Epirubicin—prostate cancer	0.000313	0.000488	CcSEcCtD
Methysergide—Asthenia—Capecitabine—prostate cancer	0.000313	0.000488	CcSEcCtD
Methysergide—Malaise—Doxorubicin—prostate cancer	0.00031	0.000484	CcSEcCtD
Methysergide—Diarrhoea—Docetaxel—prostate cancer	0.000308	0.00048	CcSEcCtD
Methysergide—Abdominal pain—Prednisone—prostate cancer	0.000307	0.000479	CcSEcCtD
Methysergide—Body temperature increased—Prednisone—prostate cancer	0.000307	0.000479	CcSEcCtD
Methysergide—Oedema—Epirubicin—prostate cancer	0.000304	0.000474	CcSEcCtD
Methysergide—Convulsion—Doxorubicin—prostate cancer	0.000298	0.000465	CcSEcCtD
Methysergide—Diarrhoea—Capecitabine—prostate cancer	0.000298	0.000465	CcSEcCtD
Methysergide—Dizziness—Docetaxel—prostate cancer	0.000298	0.000464	CcSEcCtD
Methysergide—Thrombocytopenia—Epirubicin—prostate cancer	0.000297	0.000464	CcSEcCtD
Methysergide—Tachycardia—Epirubicin—prostate cancer	0.000296	0.000462	CcSEcCtD
Methysergide—Chest pain—Doxorubicin—prostate cancer	0.000293	0.000457	CcSEcCtD
Methysergide—Arthralgia—Doxorubicin—prostate cancer	0.000293	0.000457	CcSEcCtD
Methysergide—Myalgia—Doxorubicin—prostate cancer	0.000293	0.000457	CcSEcCtD
Methysergide—Discomfort—Doxorubicin—prostate cancer	0.00029	0.000452	CcSEcCtD
Methysergide—Dizziness—Capecitabine—prostate cancer	0.000288	0.000449	CcSEcCtD
Methysergide—Vomiting—Docetaxel—prostate cancer	0.000286	0.000446	CcSEcCtD
Methysergide—Rash—Docetaxel—prostate cancer	0.000284	0.000443	CcSEcCtD
Methysergide—Dermatitis—Docetaxel—prostate cancer	0.000284	0.000442	CcSEcCtD
Methysergide—Oedema—Doxorubicin—prostate cancer	0.000281	0.000438	CcSEcCtD
Methysergide—Asthenia—Prednisone—prostate cancer	0.000279	0.000434	CcSEcCtD
Methysergide—Vomiting—Capecitabine—prostate cancer	0.000277	0.000432	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000277	0.000431	CcSEcCtD
Methysergide—Thrombocytopenia—Doxorubicin—prostate cancer	0.000275	0.000429	CcSEcCtD
Methysergide—Rash—Capecitabine—prostate cancer	0.000275	0.000429	CcSEcCtD
Methysergide—Insomnia—Epirubicin—prostate cancer	0.000275	0.000428	CcSEcCtD
Methysergide—Dermatitis—Capecitabine—prostate cancer	0.000275	0.000428	CcSEcCtD
Methysergide—Tachycardia—Doxorubicin—prostate cancer	0.000274	0.000428	CcSEcCtD
Methysergide—Paraesthesia—Epirubicin—prostate cancer	0.000273	0.000425	CcSEcCtD
Methysergide—Dyspnoea—Epirubicin—prostate cancer	0.000271	0.000422	CcSEcCtD
Methysergide—Somnolence—Epirubicin—prostate cancer	0.00027	0.000421	CcSEcCtD
Methysergide—Nausea—Docetaxel—prostate cancer	0.000267	0.000417	CcSEcCtD
Methysergide—Dyspepsia—Epirubicin—prostate cancer	0.000267	0.000417	CcSEcCtD
Methysergide—Diarrhoea—Prednisone—prostate cancer	0.000266	0.000414	CcSEcCtD
Methysergide—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000262	0.000409	CcSEcCtD
Methysergide—Fatigue—Epirubicin—prostate cancer	0.000262	0.000408	CcSEcCtD
Methysergide—Pain—Epirubicin—prostate cancer	0.00026	0.000405	CcSEcCtD
Methysergide—Constipation—Epirubicin—prostate cancer	0.00026	0.000405	CcSEcCtD
Methysergide—Nausea—Capecitabine—prostate cancer	0.000259	0.000404	CcSEcCtD
Methysergide—Dizziness—Prednisone—prostate cancer	0.000257	0.0004	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000256	0.000399	CcSEcCtD
Methysergide—Insomnia—Doxorubicin—prostate cancer	0.000254	0.000396	CcSEcCtD
Methysergide—Paraesthesia—Doxorubicin—prostate cancer	0.000252	0.000393	CcSEcCtD
Methysergide—Dyspnoea—Doxorubicin—prostate cancer	0.00025	0.000391	CcSEcCtD
Methysergide—Feeling abnormal—Epirubicin—prostate cancer	0.00025	0.00039	CcSEcCtD
Methysergide—Somnolence—Doxorubicin—prostate cancer	0.00025	0.000389	CcSEcCtD
Methysergide—Gastrointestinal pain—Epirubicin—prostate cancer	0.000248	0.000387	CcSEcCtD
Methysergide—Dyspepsia—Doxorubicin—prostate cancer	0.000247	0.000386	CcSEcCtD
Methysergide—Vomiting—Prednisone—prostate cancer	0.000247	0.000385	CcSEcCtD
Methysergide—Rash—Prednisone—prostate cancer	0.000245	0.000382	CcSEcCtD
Methysergide—Dermatitis—Prednisone—prostate cancer	0.000245	0.000381	CcSEcCtD
Methysergide—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000243	0.000378	CcSEcCtD
Methysergide—Fatigue—Doxorubicin—prostate cancer	0.000242	0.000378	CcSEcCtD
Methysergide—Pain—Doxorubicin—prostate cancer	0.00024	0.000375	CcSEcCtD
Methysergide—Constipation—Doxorubicin—prostate cancer	0.00024	0.000375	CcSEcCtD
Methysergide—Abdominal pain—Epirubicin—prostate cancer	0.00024	0.000374	CcSEcCtD
Methysergide—Body temperature increased—Epirubicin—prostate cancer	0.00024	0.000374	CcSEcCtD
Methysergide—Feeling abnormal—Doxorubicin—prostate cancer	0.000231	0.000361	CcSEcCtD
Methysergide—Nausea—Prednisone—prostate cancer	0.000231	0.00036	CcSEcCtD
Methysergide—Gastrointestinal pain—Doxorubicin—prostate cancer	0.00023	0.000358	CcSEcCtD
Methysergide—Body temperature increased—Doxorubicin—prostate cancer	0.000222	0.000346	CcSEcCtD
Methysergide—Abdominal pain—Doxorubicin—prostate cancer	0.000222	0.000346	CcSEcCtD
Methysergide—Asthenia—Epirubicin—prostate cancer	0.000218	0.00034	CcSEcCtD
Methysergide—Diarrhoea—Epirubicin—prostate cancer	0.000208	0.000324	CcSEcCtD
Methysergide—Asthenia—Doxorubicin—prostate cancer	0.000202	0.000314	CcSEcCtD
Methysergide—Dizziness—Epirubicin—prostate cancer	0.000201	0.000313	CcSEcCtD
Methysergide—Vomiting—Epirubicin—prostate cancer	0.000193	0.000301	CcSEcCtD
Methysergide—Diarrhoea—Doxorubicin—prostate cancer	0.000192	0.0003	CcSEcCtD
Methysergide—Rash—Epirubicin—prostate cancer	0.000191	0.000299	CcSEcCtD
Methysergide—Dermatitis—Epirubicin—prostate cancer	0.000191	0.000298	CcSEcCtD
Methysergide—Dizziness—Doxorubicin—prostate cancer	0.000186	0.00029	CcSEcCtD
Methysergide—Nausea—Epirubicin—prostate cancer	0.00018	0.000281	CcSEcCtD
Methysergide—Vomiting—Doxorubicin—prostate cancer	0.000179	0.000279	CcSEcCtD
Methysergide—Rash—Doxorubicin—prostate cancer	0.000177	0.000276	CcSEcCtD
Methysergide—Dermatitis—Doxorubicin—prostate cancer	0.000177	0.000276	CcSEcCtD
Methysergide—Nausea—Doxorubicin—prostate cancer	0.000167	0.00026	CcSEcCtD
Methysergide—HTR2A—Signaling Pathways—LEP—prostate cancer	1.66e-05	6.08e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—GSK3B—prostate cancer	1.65e-05	6.06e-05	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—AKT1—prostate cancer	1.65e-05	6.06e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CASP3—prostate cancer	1.65e-05	6.05e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CASP3—prostate cancer	1.65e-05	6.04e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL2—prostate cancer	1.65e-05	6.04e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL2—prostate cancer	1.65e-05	6.03e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CAV1—prostate cancer	1.64e-05	6.02e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TP53—prostate cancer	1.64e-05	6.02e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—INS—prostate cancer	1.64e-05	6.01e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—IL6—prostate cancer	1.64e-05	6.01e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CB—prostate cancer	1.64e-05	6e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—IL6—prostate cancer	1.64e-05	6e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CASP3—prostate cancer	1.64e-05	6e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CDKN1B—prostate cancer	1.64e-05	6e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL2—prostate cancer	1.64e-05	5.99e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—INS—prostate cancer	1.63e-05	5.98e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—IL6—prostate cancer	1.63e-05	5.96e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KDR—prostate cancer	1.63e-05	5.96e-05	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—AKT1—prostate cancer	1.62e-05	5.93e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CREBBP—prostate cancer	1.61e-05	5.89e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CCND1—prostate cancer	1.61e-05	5.89e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CCND1—prostate cancer	1.6e-05	5.88e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CASP3—prostate cancer	1.6e-05	5.88e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL2—prostate cancer	1.6e-05	5.87e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—PIK3CA—prostate cancer	1.6e-05	5.87e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CREBBP—prostate cancer	1.6e-05	5.86e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CCND1—prostate cancer	1.59e-05	5.84e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—IL6—prostate cancer	1.59e-05	5.84e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CTNNB1—prostate cancer	1.59e-05	5.83e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CTNNB1—prostate cancer	1.59e-05	5.82e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IGF1—prostate cancer	1.59e-05	5.82e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—ESR1—prostate cancer	1.58e-05	5.8e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—EGFR—prostate cancer	1.58e-05	5.79e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IGF1—prostate cancer	1.58e-05	5.79e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CTNNB1—prostate cancer	1.58e-05	5.78e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CXCL8—prostate cancer	1.57e-05	5.77e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—EGFR—prostate cancer	1.57e-05	5.76e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CCND1—prostate cancer	1.56e-05	5.72e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MMP9—prostate cancer	1.56e-05	5.71e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MMP9—prostate cancer	1.56e-05	5.71e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CDKN1A—prostate cancer	1.55e-05	5.69e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CDKN1A—prostate cancer	1.55e-05	5.69e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTEN—prostate cancer	1.55e-05	5.68e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TP53—prostate cancer	1.55e-05	5.68e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTEN—prostate cancer	1.55e-05	5.68e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MMP9—prostate cancer	1.55e-05	5.67e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—BAD—prostate cancer	1.55e-05	5.67e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CTNNB1—prostate cancer	1.55e-05	5.66e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CDKN1A—prostate cancer	1.54e-05	5.65e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTEN—prostate cancer	1.54e-05	5.64e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CDKN1B—prostate cancer	1.54e-05	5.63e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAP2K1—prostate cancer	1.53e-05	5.62e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAP2K1—prostate cancer	1.53e-05	5.59e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CD—prostate cancer	1.52e-05	5.58e-05	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—AKT1—prostate cancer	1.52e-05	5.57e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CD—prostate cancer	1.52e-05	5.55e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MMP9—prostate cancer	1.52e-05	5.55e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—AKT1—prostate cancer	1.51e-05	5.54e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—AKT1—prostate cancer	1.51e-05	5.54e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CDKN1A—prostate cancer	1.51e-05	5.53e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—PIK3CA—prostate cancer	1.51e-05	5.53e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SERPINE1—prostate cancer	1.51e-05	5.52e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTEN—prostate cancer	1.51e-05	5.52e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CASP3—prostate cancer	1.51e-05	5.52e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL2—prostate cancer	1.5e-05	5.51e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IL6—prostate cancer	1.5e-05	5.51e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—PIK3CA—prostate cancer	1.5e-05	5.5e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—AKT1—prostate cancer	1.5e-05	5.5e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SERPINE1—prostate cancer	1.5e-05	5.49e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CG—prostate cancer	1.5e-05	5.49e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APC—prostate cancer	1.5e-05	5.49e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—IL6—prostate cancer	1.5e-05	5.48e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—KRAS—prostate cancer	1.49e-05	5.47e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—KRAS—prostate cancer	1.48e-05	5.44e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IRS1—prostate cancer	1.48e-05	5.42e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGF—prostate cancer	1.48e-05	5.42e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EP300—prostate cancer	1.48e-05	5.42e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EP300—prostate cancer	1.48e-05	5.41e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—AKT1—prostate cancer	1.47e-05	5.39e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EP300—prostate cancer	1.47e-05	5.38e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CCND1—prostate cancer	1.47e-05	5.37e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—FGF2—prostate cancer	1.46e-05	5.35e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CTNNB1—prostate cancer	1.45e-05	5.32e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—FGF2—prostate cancer	1.45e-05	5.32e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NOS3—prostate cancer	1.44e-05	5.27e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SRC—prostate cancer	1.44e-05	5.27e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—GSK3B—prostate cancer	1.44e-05	5.27e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EP300—prostate cancer	1.44e-05	5.26e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SRC—prostate cancer	1.44e-05	5.26e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NOS3—prostate cancer	1.43e-05	5.25e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SRC—prostate cancer	1.43e-05	5.23e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MMP9—prostate cancer	1.42e-05	5.22e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CDKN1A—prostate cancer	1.42e-05	5.2e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IL6—prostate cancer	1.42e-05	5.2e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—INS—prostate cancer	1.42e-05	5.19e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTEN—prostate cancer	1.42e-05	5.19e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—VEGFA—prostate cancer	1.4e-05	5.13e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—VEGFA—prostate cancer	1.4e-05	5.13e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—JAK2—prostate cancer	1.4e-05	5.12e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SRC—prostate cancer	1.4e-05	5.12e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—JAK2—prostate cancer	1.39e-05	5.1e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—VEGFA—prostate cancer	1.39e-05	5.09e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CREBBP—prostate cancer	1.39e-05	5.09e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—STAT3—prostate cancer	1.39e-05	5.08e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—AKT1—prostate cancer	1.39e-05	5.08e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—STAT3—prostate cancer	1.38e-05	5.08e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—AKT1—prostate cancer	1.38e-05	5.06e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—STAT3—prostate cancer	1.38e-05	5.04e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IGF1—prostate cancer	1.37e-05	5.02e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—PIK3CA—prostate cancer	1.37e-05	5.02e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MDM2—prostate cancer	1.36e-05	5e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—EGFR—prostate cancer	1.36e-05	5e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—PIK3CA—prostate cancer	1.36e-05	5e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—VEGFA—prostate cancer	1.36e-05	4.99e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MDM2—prostate cancer	1.36e-05	4.98e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EP300—prostate cancer	1.35e-05	4.95e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—STAT3—prostate cancer	1.35e-05	4.94e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—ERBB2—prostate cancer	1.35e-05	4.93e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—ERBB2—prostate cancer	1.34e-05	4.91e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CB—prostate cancer	1.33e-05	4.87e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAP2K1—prostate cancer	1.32e-05	4.86e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CB—prostate cancer	1.32e-05	4.84e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CD—prostate cancer	1.32e-05	4.82e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SRC—prostate cancer	1.31e-05	4.81e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—AKT1—prostate cancer	1.31e-05	4.79e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—PIK3CA—prostate cancer	1.3e-05	4.78e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SERPINE1—prostate cancer	1.3e-05	4.77e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—KRAS—prostate cancer	1.29e-05	4.72e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MYC—prostate cancer	1.29e-05	4.72e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MYC—prostate cancer	1.29e-05	4.72e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TGFB1—prostate cancer	1.29e-05	4.71e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TGFB1—prostate cancer	1.28e-05	4.7e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MYC—prostate cancer	1.28e-05	4.69e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—VEGFA—prostate cancer	1.28e-05	4.68e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CXCL8—prostate cancer	1.28e-05	4.68e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TGFB1—prostate cancer	1.28e-05	4.67e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CXCL8—prostate cancer	1.27e-05	4.65e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—STAT3—prostate cancer	1.27e-05	4.64e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—FGF2—prostate cancer	1.26e-05	4.62e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EGFR—prostate cancer	1.26e-05	4.62e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EGFR—prostate cancer	1.26e-05	4.61e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MYC—prostate cancer	1.25e-05	4.59e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EGFR—prostate cancer	1.25e-05	4.58e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TGFB1—prostate cancer	1.25e-05	4.58e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	1.25e-05	4.57e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NOS3—prostate cancer	1.24e-05	4.56e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CDKN1B—prostate cancer	1.24e-05	4.54e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	1.23e-05	4.52e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—AKT1—prostate cancer	1.23e-05	4.49e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EGFR—prostate cancer	1.22e-05	4.49e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CASP3—prostate cancer	1.22e-05	4.48e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL2—prostate cancer	1.22e-05	4.47e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CASP3—prostate cancer	1.22e-05	4.45e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL6—prostate cancer	1.21e-05	4.45e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL2—prostate cancer	1.21e-05	4.45e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—JAK2—prostate cancer	1.21e-05	4.43e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL6—prostate cancer	1.21e-05	4.42e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—KRAS—prostate cancer	1.19e-05	4.36e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—KRAS—prostate cancer	1.19e-05	4.36e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCND1—prostate cancer	1.19e-05	4.36e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	1.18e-05	4.34e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCND1—prostate cancer	1.18e-05	4.33e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—KRAS—prostate cancer	1.18e-05	4.33e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MDM2—prostate cancer	1.18e-05	4.32e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	1.18e-05	4.31e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MYC—prostate cancer	1.18e-05	4.31e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TGFB1—prostate cancer	1.17e-05	4.3e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	1.17e-05	4.29e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—ERBB2—prostate cancer	1.16e-05	4.26e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—KRAS—prostate cancer	1.16e-05	4.24e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MMP9—prostate cancer	1.15e-05	4.23e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EGFR—prostate cancer	1.15e-05	4.22e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	1.15e-05	4.22e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MMP9—prostate cancer	1.15e-05	4.21e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTEN—prostate cancer	1.15e-05	4.21e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	1.15e-05	4.2e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	1.14e-05	4.19e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTEN—prostate cancer	1.14e-05	4.18e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—AKT1—prostate cancer	1.12e-05	4.1e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—AKT1—prostate cancer	1.11e-05	4.08e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CXCL8—prostate cancer	1.1e-05	4.04e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EP300—prostate cancer	1.09e-05	4.01e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PIK3CA—prostate cancer	1.09e-05	4.01e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PIK3CA—prostate cancer	1.09e-05	4e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EP300—prostate cancer	1.09e-05	3.99e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—KRAS—prostate cancer	1.09e-05	3.98e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	1.09e-05	3.98e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	1.08e-05	3.95e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	1.07e-05	3.9e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SRC—prostate cancer	1.06e-05	3.9e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	1.06e-05	3.89e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SRC—prostate cancer	1.06e-05	3.88e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TP53—prostate cancer	1.06e-05	3.88e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TP53—prostate cancer	1.06e-05	3.87e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CASP3—prostate cancer	1.06e-05	3.87e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL2—prostate cancer	1.05e-05	3.86e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TP53—prostate cancer	1.05e-05	3.85e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL6—prostate cancer	1.05e-05	3.84e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—VEGFA—prostate cancer	1.04e-05	3.8e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—VEGFA—prostate cancer	1.03e-05	3.78e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TP53—prostate cancer	1.03e-05	3.77e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCND1—prostate cancer	1.03e-05	3.76e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—STAT3—prostate cancer	1.03e-05	3.76e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—STAT3—prostate cancer	1.02e-05	3.74e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	1.02e-05	3.73e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	9.98e-06	3.66e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MMP9—prostate cancer	9.97e-06	3.65e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	9.94e-06	3.64e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTEN—prostate cancer	9.91e-06	3.63e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL6—prostate cancer	9.68e-06	3.55e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL6—prostate cancer	9.67e-06	3.55e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKT1—prostate cancer	9.67e-06	3.54e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TP53—prostate cancer	9.66e-06	3.54e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL6—prostate cancer	9.61e-06	3.52e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MYC—prostate cancer	9.54e-06	3.49e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TGFB1—prostate cancer	9.51e-06	3.49e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MYC—prostate cancer	9.49e-06	3.48e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TGFB1—prostate cancer	9.46e-06	3.47e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EP300—prostate cancer	9.45e-06	3.46e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL6—prostate cancer	9.41e-06	3.45e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EGFR—prostate cancer	9.33e-06	3.42e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EGFR—prostate cancer	9.28e-06	3.4e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SRC—prostate cancer	9.19e-06	3.37e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—VEGFA—prostate cancer	8.95e-06	3.28e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKT1—prostate cancer	8.93e-06	3.27e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKT1—prostate cancer	8.92e-06	3.27e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKT1—prostate cancer	8.87e-06	3.25e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—STAT3—prostate cancer	8.87e-06	3.25e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL6—prostate cancer	8.84e-06	3.24e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KRAS—prostate cancer	8.81e-06	3.23e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KRAS—prostate cancer	8.77e-06	3.21e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKT1—prostate cancer	8.68e-06	3.18e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MYC—prostate cancer	8.24e-06	3.02e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TGFB1—prostate cancer	8.22e-06	3.01e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT1—prostate cancer	8.16e-06	2.99e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	8.1e-06	2.97e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGFR—prostate cancer	8.06e-06	2.95e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	8.05e-06	2.95e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TP53—prostate cancer	7.83e-06	2.87e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TP53—prostate cancer	7.79e-06	2.86e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KRAS—prostate cancer	7.61e-06	2.79e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL6—prostate cancer	7.17e-06	2.63e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL6—prostate cancer	7.13e-06	2.61e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	6.99e-06	2.56e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TP53—prostate cancer	6.77e-06	2.48e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT1—prostate cancer	6.61e-06	2.42e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT1—prostate cancer	6.58e-06	2.41e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL6—prostate cancer	6.19e-06	2.27e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT1—prostate cancer	5.71e-06	2.09e-05	CbGpPWpGaD
